Repurposed nasal antibiotic neomycin shows promise in preventing and treating respiratory viral infections

Intranasal administration of neomycin sulfate in murine models shows promise as a prophylactic and therapeutic agent against respiratory viruses like influenza A and SARS-CoV-2 by inducing interferon-stimulated gene (ISG) expression, independent of microbiota and interferon activation.

Mainz Biomed Announces Stock Split – Biotech Investments

Issuer: Mainz BioMed N.V. / Key word(s): Miscellaneous 29.11.2024 / 14:45 CET/CEST The issuer is solely responsible for the content of this announcement. Mainz Biomed

November 30, 2024

Neoadjuvant Cemiplimab Shows Potential as an Option for Cutaneous SCC

MADRID — Treatment with cemiplimab (Libtayo) followed by surgery showed encouraging survival rates in patients with resectable stage II-IV cutaneous squamous cell carcinoma (SCC), according

October 26, 2023

3 issues to watch in pharma in 2024

As another year comes to an end and the world seems to hit the proverbial pause button, the temptation to look ahead is too great

December 27, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.